TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-perceived communication function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric mean antibody titer against S. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Index of prophylactic effectiveness of Pneumo 23 vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative risk of the disease in the immunized group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TXB(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aspirin-Induced Urticaria (AIU) confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anteversion angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inclination angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of cup implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: disability-free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: PLR (Platelet-to-Lymphocyte Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical joint symptoms as measured by the Lequesne index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-progression rates for stage I/II hips
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Flow (FEF)25-75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: shifted-view recognition impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of intrusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Life satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: shoulder range of motion (PROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Processing speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Continence at catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continence at 7 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pad usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: islet mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: islet functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in foot volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Related Functioning Inventory (PRFI) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Remission of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success rate at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHRQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Insulin: glucagon ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saturated fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: TF and PAI‐1 secretion in HUVEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL particle number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean LDL particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of dissection-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular access-site complications
Endpoint domain: Adverse events/effects
Primary endpoint: self‐selected walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosage of analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications (pain, restlessness, drowsiness, nausea, vomiting)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of developing follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Daily menstrual flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: subjective ratings of quality of day and night vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total ED Length of Stay (LOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consultations completed without ED arrival
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ED50 for motor block of intrathecal ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion CNR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal glucose intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean adherence to isoniazid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial hyperglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in CFUs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Splanchnic circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relative gene expression of MMP-1 and MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Protein expression of MMP-1 and MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Susceptibility to lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-QOL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: WPAI:IBS scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: EQ-5D Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residual tumor detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Higher monetary offers made
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rejection of unfair offers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Emergence Delirium (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence from anesthesia speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: student knowledge of asthma
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: participation in life activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Composite outcome of death or major neurodevelopmental impairment
Endpoint domain: Mortality/survival
Primary endpoint: Major neurodevelopmental impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiovascular mortality risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: Total mortality risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: Mean reduction in ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate effects of isopropanol 70% compared to n-propanol 60%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained effects of isopropanol 80% and 90% compared to n-propanol 60%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 3-month costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sedentary levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Light physical activity (PA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to vigorous physical activity (MVPA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall rate at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Success probability at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Survival probability at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Increased ACTH and cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduced risk of relapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak plasma concentrations (Cmax) of fulvestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall exposure to fulvestrant (AUC(0-28))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian variation in free IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Circadian variation in free IGF‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Circadian variation of total IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate Pressure Product (RPP) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arousal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes toward information-seeking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean acylated ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: appetite perceptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total PYY concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of free cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lumbar extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back and leg pain scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma concentration of sVEGFR‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute neutrophil nadir counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: gestation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant metastasis rate
Endpoint domain: Mortality/survival
Primary endpoint: Estimated survival at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients receiving heart transplantation at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Length of stay in rehabilitation ward
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total number of infection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: bleaching efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rhinitis total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of resistance to antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recession Reduction (Rec Red)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized Tissue Thickness (KTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Root Coverage (CRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary retention frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Suprapubic discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methodological quality score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: visual vigilance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: choice reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum average arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depth of stromal demarcation line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED visits or readmissions
Endpoint domain: Mortality/survival
Primary endpoint: ocular staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Pain Thresholds (PPTs) over upper trapezius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pressure Pain Thresholds (PPTs) over masseter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Substance use prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of the macular hole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time from colonoscope insertion to caecal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median total procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates for caecal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum prealbumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean HAMD-24 change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of global coherence in stories
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Whitening effect (ΔL*, Δa*, Δb*, ΔE*, delta shade guide)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher consumption on the Timeline Followback (TLFB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory clinical result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced spondylolisthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiac complications
Endpoint domain: Adverse events/effects
Primary endpoint: cost savings from CAUTI hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: nutritional outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discrimination performance (/ba/-/da/ percent correct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASSR score (percent responses present)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering plasma levels of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Partnership scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attachment scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in degree of erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in mean area of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean duration of crying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean number of regurgitations per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean number of evacuations per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of dental calculus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in vein categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ulcerations and swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Change in LCI from baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxford Handicap Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: decrease in usual drinks per occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in maximum drinks per occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in signal from the stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in signal from the duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in conspicuousness of the distal common duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in conspicuousness of the proximal common duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC per milligram dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impression cytology score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear ferning patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertension self‐management behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CA19-9 decrease ≥20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUClast) for R-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUClast) for S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (C max) for R-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (C max) for S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of IM regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean levels of total cholesterol, HDL cholesterol, and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3- and 5-year cumulative survival rates
Endpoint domain: Mortality/survival
Primary endpoint: RB of neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensitivity for detecting polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of mucosal surface visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marked depressive symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Dietetic knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Full persistence at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence
Endpoint domain: Adverse events/effects
Primary endpoint: pain associated with tonsillitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain on swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erythema and inflammation of the pharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tonsil size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first-phase beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall and severe toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost savings from basiliximab use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of Ropivacaine vs Bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of cardiac abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: inattentive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oppositional symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes